Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: A tale of two choices -Counterpoint

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 11, 2007, Pages 2210-2212

  Fabian, Carol ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; RALOXIFENE; TAMOXIFEN;

BREAST TUMOR; CLINICAL TRIAL; FEMALE; HUMAN; METABOLISM; NOTE; POSTMENOPAUSE;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; POSTMENOPAUSE; RALOXIFENE; TAMOXIFEN;

EID: 43549085352     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-1065     Document Type: Review

References (23)

1. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-32. (Pubitemid 36511623)
2. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1study. J Natl Cancer Inst 2005; 97:1652-62. (Pubitemid 41672231)
3. Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 2004;22:4951-7. (Pubitemid 46638620)
4. Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 2004;100:1800-6. (Pubitemid 38529556)
5. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001;8:580-5. (Pubitemid 32735038)
6. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE Randomized Trial. Multiple outcomes of raloxifene evaluation. JAMA 1999;281:2189-97. (Pubitemid 29275701)
7. Vogel VG, Costantino JP, Wickerham DL, et al.; National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
8. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2742-51.
9. American Cancer Society. Cancer facts and figures 2007. Atlanta: American Cancer Society; 2007.
10. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1Study. J Natl Cancer Inst 1998;90: 1371-88. (Pubitemid 28439961)
11. Frasor J, Chang EC, Komm B, et al. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 2006;66:7334-40. (Pubitemid 44197716)
12. Martino S, Cauley JA, Barrett-Connor E, et al. CORE Investigators. Continuing Outcomes Relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61. (Pubitemid 39654569)
13. Barrett-Connor E, Mosca L, Collins P, et al. Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37. (Pubitemid 44050394)
14. Porter D, Lahti-Domenici J, Keshaviah A, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 2003;1:362-75. (Pubitemid 36437922)
15. Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 2006;8:R61.
16. Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004;6: 17-32. (Pubitemid 38903159)
17. Cuzick J, Forbes JF, Sestak I, et al. International Breast Cancer Intervention Study I Investigators. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272-82. (Pubitemid 47073490)
18. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007;99: 283-90. (Pubitemid 47073491)
19. Heringa M. Review on raloxifene: profile of a selective estrogen receptor modulator. Int J Clin Pharmacol Ther 2003;41:331-45. (Pubitemid 36980563)
20. Snyder KR, Sparano N, Malinowski JM. Raloxifene hydrochloride. Am J Health Syst Pharm 2000;57:1669-75.
21. Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L, Jr. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update 2000;6:212-24. (Pubitemid 30348890)
22. Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 2003; 42:361-72. (Pubitemid 36433876)
23. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2006;101:113-21.